| 000 | 01561 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250516050204.0 | ||
| 264 | 0 | _c20111220 | |
| 008 | 201112s 0 0 eng d | ||
| 022 | _a1751-4266 | ||
| 024 | 7 |
_a10.1097/SPC.0b013e3283499c93 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWilson, C | |
| 245 | 0 | 0 |
_aAdjuvant therapy with bone-targeted agents. _h[electronic resource] |
| 260 |
_bCurrent opinion in supportive and palliative care _cSep 2011 |
||
| 300 |
_a241-50 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAdjuvants, Pharmaceutic _xtherapeutic use |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAromatase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aDenosumab |
| 650 | 0 | 4 |
_aDiphosphonates _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aOsteoporosis _xchemically induced |
| 650 | 0 | 4 | _aPremenopause |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aRANK Ligand _xtherapeutic use |
| 700 | 1 | _aColeman, R E | |
| 773 | 0 |
_tCurrent opinion in supportive and palliative care _gvol. 5 _gno. 3 _gp. 241-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/SPC.0b013e3283499c93 _zAvailable from publisher's website |
| 999 |
_c21032095 _d21032095 |
||